ABBISKO-B (02256) announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Co., Ltd. (ABBISKO), presented long-term efficacy, safety, and patient-reported outcome data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for tenosynovial giant cell tumor (TGCT) patients at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting in a poster format.

The long-term analysis demonstrated that continued treatment with pimicotinib provided sustained improvement in tumor response and further enhancements in patient-reported outcomes (including pain and function) for TGCT patients, while maintaining an acceptable safety profile. These findings reinforce the long-term therapeutic potential of pimicotinib for eligible patients.